Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$117.10 USD

117.10
9,962,652

-0.13 (-0.11%)

Updated Sep 20, 2024 09:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Merck Loses Around $32B in 3 Months: Time to Sell the Stock?

by Kinjel Shah

Declining estimates and the recent price drop make investors skeptical about holding MRK stock.

Merck (MRK) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

Merck's Keytruda Obtains its First FDA Approval for Mesothelioma

by Zacks Equity Research

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

by Zacks Equity Research

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

by Zacks Equity Research

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

by Zacks Equity Research

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

by Zacks Equity Research

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

by Zacks Equity Research

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

Here's Why Merck (MRK) Gained But Lagged the Market Today

by Zacks Equity Research

Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

by Zacks Equity Research

BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

by Zacks Equity Research

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

by Zacks Equity Research

Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

by Zacks Equity Research

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Merck (MRK) Stock Moves -0.63%: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $117.84, moving -0.63% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More

by Kinjel Shah

European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

by Zacks Equity Research

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

by Zacks Equity Research

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

by Zacks Equity Research

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

Merck (MRK) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

by Zacks Equity Research

MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs

by Kinjel Shah

LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.

Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?

by Zacks Equity Research

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.